IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model

Xuesong Wu, Daniel K. Hsu, Kang Hsin Wang, Yuanshen Huang, Lindsay Mendoza, Youwen Zhou, Samuel T Hwang

Research output: Contribution to journalArticle


A crucial question pertains to a role of IL-10 as a tumorigenic factor, or just a marker of advanced disease in cutaneous T-cell lymphoma (CTCL). Herein, we measured significantly elevated IL-10 mRNA in a cohort of skin samples of patients with CTCL. Increased IL-10 was also detected in the tumor microenvironment of an established inflammation-dependent murine model of using MBL2 T lymphoma cells. Conditioned media from MBL2 cells was able to stimulate IL-10 production in bone marrow-derived macrophages in an IL-4-dependent manner. Implanted MBL2 T-cell lymphomas in IL-10KO mice were 50% smaller, accompanied by decreased numbers of infiltrating macrophages and reduced efficiency of M2-polarization compared with wild-type mice. With anti-IL-10R mAb treatment, both wild-type tumor-bearing mice and IL-10KO mice exhibited a further growth inhibition. Our data indicate that targeting IL-10 signaling with neutralizing antibodies to IL-10 or its receptor may have a great potential for advanced CTCL therapy.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
StateAccepted/In press - Jan 1 2018



  • CTCL (cutaneous T-cell lymphoma)
  • IL-10 (interleukin-10)
  • macrophages
  • tumor immunology

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this